Focal therapy for prostate cancer
Peter T. Scardino
p175 | doi:10.1038/nrurol.2009.52
Table of contents
April 2009 Vol 6 No 4
Free Sample Issue
Full text content of the April 2009 issue is freely available in both HTML and PDF formats.
Editorial
Research Highlights
Bladder cancer: Inequalities in bladder cancer survival | PDF (114 KB)
p177 | doi:10.1038/nrurol.2009.30
Prostate cancer: Post-ADT PSA kinetics predict survival | PDF (81 KB)
p178 | doi:10.1038/nrurol.2009.32
PSA structure in prostate cancer | PDF (55 KB)
p178 | doi:10.1038/nrurol.2009.38
Prostate cancer: Sexual activity link with prostate cancer | PDF (62 KB)
p179 | doi:10.1038/nrurol.2009.34
In brief
Prostate cancer | Sexual dysfunction | Urinary incontinence | PDF (49 KB)
p179 | doi:10.1038/nrurol.2009.44
Testicular cancer: Marijuana use linked with testicular cancer | PDF (92 KB)
p180 | doi:10.1038/nrurol.2009.33
Benign prostatic hyperplasia: Alfuzosin improves sexual function | PDF (70 KB)
p180 | doi:10.1038/nrurol.2009.36
Risk factors: ED at young age predicts heart disease | PDF (107 KB)
p181 | doi:10.1038/nrurol.2009.35
Pediatrics: Pediatric dysfunctional voiding treated with tamsulosin | PDF (51 KB)
p182 | doi:10.1038/nrurol.2009.39
Pediatrics: Melamine ingestion and prematurity associated with urolithiasis | PDF (70 KB)
p182 | doi:10.1038/nrurol.2009.42
News and Views
Prostatitis: No benefit of 
-blockers for chronic prostatitis
Florian M. E. Wagenlehner & Wolfgang Weidner
p183 | doi:10.1038/nrurol.2009.45
A randomized controlled trial has questioned the widespread use of the 
-blocker alfuzosin as an empirical treatment for chronic prostatitis–chronic pelvic pain syndrome. Instead, only a small subgroup of patients might benefit from this therapy.
Prostate Cancer: Regeneration of interest in the prostate
Anne T. Collins & Norman J. Maitland
p184 | doi:10.1038/nrurol.2009.48
The growth of prostate acini from single cell implants in mice is a major breakthrough. Such results have important clinical implications, and will ultimately change the treatment paradigm for prostatic disease.
Prostate cancer: Neither vitamin E nor selenium prevent prostate cancer
Naomi E. Allen & Timothy J. Key
p187 | doi:10.1038/nrurol.2009.47
Data on the value of dietary supplements in reducing the risk of developing prostate cancer have been conflicting; however, two large randomized trials have indicated that prostate cancer risk is not reduced by the long-term use of vitamin E, vitamin C or selenium supplements.
Pathology: The lottery of conventional prostate biopsy
Gerald L. Andriole
p188 | doi:10.1038/nrurol.2009.46
Increasing the number of prostate biopsy cores taken does not improve diagnostic accuracy. Instead, urologists need to think in three dimensions and use template guidance to improve cancer detection and characterization.
Reviews
Imaging techniques for prostate cancer: implications for focal therapy
Baris Turkbey, Peter A. Pinto & Peter L. Choyke
p191 | doi:10.1038/nrurol.2009.27
For patients who present with localized prostate cancer, focal therapy could be a treatment option; however, accurate imaging of the prostate is required for focal therapy to be viable. This Review by Turkbey et al. discusses the conventional methods for imaging the prostate, the new developments for targeted imaging, and the possible role of image-guided biopsy and focal therapy.
Pathologic basis of focal therapy for early-stage prostate cancer
Vladimir Mouraviev, Janice M. Mayes & Thomas J. Polascik
p205 | doi:10.1038/nrurol.2009.29
The selection of patients with prostate cancer who are suitable for focal therapy remains a controversial topic. In this Review, Mouraviev and colleagues discuss pathological insights into the biology of early-stage disease, and highlight the critical role of three-dimensional prostate mapping protocols in the localization of disease.
Sildenafil citrate for female sexual arousal disorder: a future possibility?
Corina Schoen & Gloria Bachmann
p216 | doi:10.1038/nrurol.2009.25
Female sexual arousal disorder (FSAD) is a common disorder encountered in clinical practice, but no drugs for FSAD have been approved. In this Review, Schoen and Bachmann discuss the use of sildenafil citrate, a phosphodiesterase type-5 inhibitor, for FSAD treatment. They provide the rationale for treatment, and discuss results of sildenafil citrate from past clinical studies in women with FSAD.
Case Study
A case of high-risk penile epithelioid hemangioendothelioma
Alexei Wedmid, Timothy A. Masterson, Robert G. Maki & Paul Russo
p223 | doi:10.1038/nrurol.2009.26
This Case Study describes a 48-year-old man who was referred to a specialist oncology center for management of presumed angiosarcoma. Further investigation revealed high-risk penile epithelioid hemangioendothelioma. This article highlights the spectrum of clinical behavior of this atypical epithelioid vascular tumor, and provides possible treatment options for low-risk and high-risk forms of this cancer.
Perspectives
Opinion
Integrative medicine: complementary therapies and supplements
Barrie R. Cassileth, Jyothirmai Gubili & K. Simon Yeung
p228 | doi:10.1038/nrurol.2009.41
Many patients with urologic disorders, particularly cancer, use complementary therapies as adjuncts to mainstream treatment. Accumulating evidence highlights the beneficial impact of supportive measures, such as acupuncture, yoga, meditation and physical activity, on the symptoms of patients with urologic disorders. These data, as well as studies of herbs and other dietary supplements, are discussed here.
